Key Stats for BridgeBio Pharma Stock
- Price change for BridgeBio Pharma stock: 2%
- $BBIO Stock Price as of Apr. 9: $76
- 52-Week High: $85
- $BBIO Stock Price Target: $101
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
RBC Capital just initiated coverage on BridgeBio Pharma (BBIO) stock with an Outperform rating and a $100 price target. That implies roughly 35% upside from where the stock trades today.
The call follows a survey of 40 cardiologists and conversations with key opinion leaders about Attruby, BridgeBio’s approved drug for a heart condition called transthyretin amyloidosis cardiomyopathy.
The results were encouraging.
Attruby has already helped BridgeBio Pharma’s stock triple since its approval, with shares delivering a 130% return over the past year.
See analysts’ growth forecasts and price targets for BridgeBio Pharma stock (It’s free) >>>
What the Market Is Telling Us About BridgeBio Pharma Stock
One of the biggest concerns hanging over BridgeBio Pharma stock is legal risk.
- A competitor’s drug, Vyndamax, could eventually go generic and pressure Attruby’s market position.
- But RBC’s IP lawyers think a generic is unlikely to arrive before 2031 or 2032, with Pfizer likely settling around that window.
- RBC estimates this legal dispute creates a $15-per-share swing between bull and bear scenarios — meaningful, but manageable.
Beyond Attruby, RBC sees a deep pipeline.
- Infigratinib, BridgeBio’s treatment for a bone growth disorder called achondroplasia, is viewed as best-in-class with peak sales potential of around $700 million.
- Encaleret, targeting a rare condition called ADH1 deficiency, could reach similar peak sales.
- BBP-418, which recently had an FDA application submitted ahead of schedule for a muscle disease called LGMD, could add another $600 million at peak. Jefferies goes even further, calling the BBP-418 program a potential $1 billion-plus opportunity.
RBC projects BridgeBio hitting $5 billion in top-line revenue with healthy margins.
- At a 4x revenue multiple, they value the company at $20 billion — compared to the current $14.4 billion market cap.
- The company recently posted 126% revenue growth, lending real credibility to that outlook.
Other analysts agree the setup looks attractive.
- Barclays has an Overweight rating and expects Q1 Attruby revenue of $175 million, above the $169 million consensus.
- William Blair calls BridgeBio Pharma stock a core biotech holding.
- H.C. Wainwright and Jefferies both have Buy ratings with $100 price targets.
BridgeBio Pharma stock carries a Speculative Risk designation from RBC, so this isn’t a name for everyone. But for investors comfortable with biotech risk, the combination of a proven commercial drug and a pipeline with multiple shots on goal makes the bull case hard to ignore.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does BridgeBio Pharma Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
